Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Clinical trial NCT02970292 · COMPLETED
Trial details
- NCT number
- NCT02970292
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-26
- Primary completion
- 2019-05-28
- Enrollment
- 396
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.